Press

JenaValve Appoints Kari Moore as Chief Financial Officer

JenaValve

IRVINE, Calif., May 17, 2022 (GLOBE NEWSWIRE) —JenaValve Technology, Inc. (“JenaValveor the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the appointment of Kari Moore as the Company’s CFO effective May 10th, 2022.

“We are excited to welcome Kari to the JenaValve team,” said John Kilcoyne, JenaValve’s CEO.“Kari brings over 35 years of extensive financial and operational experience in the medical device and healthcare industry. Kari’s extensive knowledge and industry expertise will be instrumental as we continue to execute our clinical strategy and move forward in our commercialization efforts of the Trilogy® Heart Valve System for the treatment of aortic valve diseases.”

Mrs. Moore joins JenaValve after most recently serving as the Chief Accounting Officer of Envista Holdings Corporation, a global dental products company, where she was responsible for the worldwide accounting, treasury, and shared services functions. Prior to joining Envista Holdings Corporation, Mrs. Moore was the Chief Accounting Officer at Applied Medical Corporation, a global medical device company providing technologies and solutions for minimally invasive and general surgery. Mrs. Moore began her carrier at PricewaterhouseCoopers, where she served as an audit partner and specialized in the life sciences industry. Over her 20-year career, Mrs. Moore took many companies public and assisted them with acquisitions, divestitures, and debt offerings. Kari received a BS in Business Administration from the University of Southern California and is a licensed CPA in the state of California.

Mrs. Moore stated, “I am thrilled to be joining JenaValve at such a pivotal time. I am excited to partner with the entire JenaValve team to continue executing our growth and value creation strategies while improving patients’ lives.”

About JenaValve

JenaValve Technology, Inc., with headquarters in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany, develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease. JenaValve is backed by Bain Capital Life Sciences and Cormorant Asset Management, as well as European and Asian investors, including Andera Partners, Gimv (Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences, VI Partners, and Peijia Medical Limited(HKEX: 9996).

Additional information is available at www.jenavalve.com.

US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

Contact:
Investor Relations
Matt Bacso, CFA
matt.bacso@gilmartinir.com

Latest News

View All
Press
JenaValve Announces Start of Commercialization of the Trilogy<sup>®</sup> Transcatheter Heart Valve System in the US
April 1, 2026
JenaValve Announces Start of Commercialization of the Trilogy® Transcatheter Heart Valve System in the US
Read More
Press
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System
March 18, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System
Read More
Press
New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves
November 24, 2025
New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves
Read More
Close Download
Close Download
The information in this Reimbursement Guide is provided for educational purposes only and is not intended to be coding or billing advice. This coding information is based upon publicly available information and is current as of April 1, 2026 and subject to change without notice. JenaValve Technology, Inc. cannot guarantee that any product or service billed with the codes listed will be covered or, if covered, the listed payment amount will be paid by any payer. It is the responsibility of the provider to select appropriate codes for each patient and to submit appropriate codes, charges, and modifiers for services rendered. Providers should contact insurers to verify correct coding procedures prior to submitting claims related to the use of JenaValve products. In all cases, providers must bill according to the rules, policies and procedures of individual payers. The medical record should document that the product or procedure was medically necessary and furnished or performed as reported. Clinical need, not reimbursement amount, should always drive clinical decision making. If you have any questions about appropriate billing for products or services, please consult your local payer. The information contained in this guide is provided to assist providers in understanding the reimbursement process. It is intended to assist providers in obtaining accurate and appropriate reimbursement for the healthcare services provided. It is not intended to increase or maximize reimbursement by any payer. It is strongly recommended that providers consult with their payer organizations with regard to local reimbursement policies. The information contained herein is provided for information purposes only and represents no statement, promise, or guarantee by JenaValve Technology, Inc. concerning levels of reimbursement, payment, or charge. Similarly, all CPT codes are supplied for information purposes only and represent no statement, promise, or guarantee by JenaValve Technology, Inc. that these codes will be appropriate or that reimbursement will be made. For additional information, please contact us at reimbursement.usa@jenavalve.com.